https://pubmed.ncbi.nlm.nih.gov/34817690/ Biliary atresia

Curr Gastroenterol Rep. 2021 Nov 24;23(12):28.
doi: 10.1007/s11894-021-00825-2.

Newborn Screening for Biliary Atresia: a Review of Current Methods

Tebyan Rabbani 1, Stephen L Guthery 2, Ryan Himes 3, Benjamin L Shneider 4, Sanjiv Harpavat 5

Abstract

Purpose of review: Biliary atresia is a serious neonatal liver disease due to obstructed bile ducts that has better outcomes when detected and treated in the first 30-45 days of life. This review examines different methods to screen newborns for biliary atresia as well as discusses observations from ongoing screening programs implemented in parts of the United States.

Recent findings: Screening strategies for biliary atresia include detecting persistent jaundice, examining stool color, testing fractionated bilirubin levels, or measuring bile acid levels from dried blood spot cards. The stool color card program is the most widely used screening strategy worldwide. An alternative approach under investigation in the United States measures fractionated bilirubin levels, which are abnormal in newborns with biliary atresia. Fractionated bilirubin screening programs require laboratories to derive reference ranges, nurseries to implement universal testing, and healthcare systems to develop infrastructure that identifies and acts upon abnormal results. Biliary atresia meets the disease-specific criteria for newborn screening. Current studies focus on developing a strategy which also meets all test-specific criteria. Such a strategy, if implemented uniformly, has the potential to accelerate treatment and reduce biliary atresia's large liver transplant burden.